In the last trading session, 2.85 million shares of the Avadel Pharmaceuticals plc (NASDAQ:AVDL) were traded, and its beta was 1.57. Most recently the company’s share price was $9.09, and it changed around $0.98 or 12.08% from the last close, which brings the market valuation of the company to $875.91M. AVDL currently trades at a discount to its 52-week high of $19.09, offering almost -110.01% off that amount. The share price’s 52-week low was $7.39, which indicates that the current value has risen by an impressive 18.7% since then. We note from Avadel Pharmaceuticals plc’s average daily trading volume that its 10-day average is 1.22 million shares, with the 3-month average coming to 1.52 million.
Avadel Pharmaceuticals plc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 9 analysts rate the stock as a Sell; another 3 rate it as Overweight. Among the rest, 0 recommended AVDL as a Hold, whereas 6 deemed it a Buy, and 0 rated it as Underweight. Avadel Pharmaceuticals plc is expected to report earnings per share of -0.04 for the current quarter.
Avadel Pharmaceuticals plc (NASDAQ:AVDL) trade information
Instantly AVDL has showed a green trend with a performance of 12.08% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 9.16 on recent trading dayincreased the stock’s daily price by 0.76%. The company’s shares are currently down -13.51% year-to-date, but still up 14.05% over the last five days. On the other hand, Avadel Pharmaceuticals plc (NASDAQ:AVDL) is -14.97% down in the 30-day period. We can see from the shorts that 11.51 million shares have been sold at a short interest cover period of 7.6 day(s).
The consensus price target as assigned by Wall Street analysts is $21, which translates to bulls needing to increase their stock price by 56.71% from its current value. Analyst projections state that AVDL is forecast to be at a low of $19 and a high of $30.
Avadel Pharmaceuticals plc (AVDL) estimates and forecasts
The year-over-year growth rate is expected to be 503.44%, up from the previous year.
Consensus estimates provided by 8 financial analysts predict the company will bring in an average of 50.04M in revenue for the current quarter. 7 analysts expect Avadel Pharmaceuticals plc to make 53.32M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 19.45M and 27.18M respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 157.22%. Forecasts for the next quarter put sales growth at 96.20%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 4.78%.
AVDL Dividends
Avadel Pharmaceuticals plc’s next quarterly earnings report is expected to be released in March.
Avadel Pharmaceuticals plc (NASDAQ:AVDL)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 4.78% of Avadel Pharmaceuticals plc shares, and 80.73% of them are in the hands of institutional investors. The stock currently has a share float of 84.78%. Avadel Pharmaceuticals plc stock is held by 234.0 institutions, with VIVO CAPITAL, LLC being the largest institutional investor. By 2024-06-30, it held 4.332% of the shares, which is about 3.97 million shares worth $55.85 million.
TRI LOCUM PARTNERS LP, with 1.2973% or 1.19 million shares worth $16.72 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
Vanguard Total Stock Market Index Fund and Janus Henderson Global Life Sciences Fund were the top two Mutual Funds as of Sep 30, 2024 . The former held 2.99 shares worth $27.14 million, making up 3.10% of all outstanding shares. On the other hand, Janus Henderson Global Life Sciences Fund held roughly 2.68 shares worth around $24.37 million, which represents about 2.78% of the total shares outstanding.
